Dual silencing of EGFR and HER2 enhances the sensitivity of gastric cancer cells to gefitinib

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Interference of STAT 5b expression enhances the chemo-sensitivity of gastric cancer cells to gefitinib by promoting mitochondrial pathway-mediated cell apoptosis

(2015) TAO SUN et al.   ONCOLOGY REPORTS

Downregulation of c-Met expression does not enhance the sensitivity of gastric cancer cell line MKN-45 to gefitinib

(2014) JIN-AN MA et al.   Molecular Medicine Reports

Differential Transcriptional Effects of EGFR Inhibitors

(2014) Miroslav Blumenberg   PLoS One

The ErbB/HER family of protein-tyrosine kinases and cancer

(2013) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer

(2011) H.-J. Nam et al.   MOLECULAR CANCER THERAPEUTICS

Anti-HER agents in gastric cancer: from bench to bedside

(2011) Lorenzo Fornaro et al.   Nature Reviews Gastroenterology & Hepatology

Critical appraisal of trastuzumab in treatment of advanced stomach cancer

(2011) Judith Meza-Junco et al.   Cancer Management and Research

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus

(2010) David H. Ilson et al.   CANCER

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

(2010) Mark E. Davis et al.   NATURE

Trastuzumab-Induced HER Reprogramming in "Resistant" Breast Carcinoma Cells

(2009) M. Narayan et al.   CANCER RESEARCH

Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

(2009) Y.-K. Yoon et al.   MOLECULAR CANCER THERAPEUTICS

EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number

(2008) M A Kim et al.   HISTOPATHOLOGY

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

(2008) David Cunningham et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

(2008) D L Wheeler et al.   ONCOGENE

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

(2008) M Scaltriti et al.   ONCOGENE

Modeling oncogene addiction using RNA interference

(2008) S. M. Rothenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA